Flow cytometry (FCM) and immunohistochemistry (IHC) confirmed that the tumor cells co-expressed T-lymphoid and myeloid antigens, and fluorescence <i>in situ</i> hybridization (FISH) detected BCR::ABL1 fusion signals in lymph node tissue, leading to the final diagnosis of <i>de novo</i> blast phase CML (BP-CML) with mixed phenotype (T-lineage and myeloid expression). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.